<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124540</url>
  </required_header>
  <id_info>
    <org_study_id>2.4.5</org_study_id>
    <nct_id>NCT00124540</nct_id>
  </id_info>
  <brief_title>Misoprostol for Preventing Postpartum Hemorrhage</brief_title>
  <official_title>Misoprostol for Preventing Postpartum Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Effective Care Research Unit, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Family Care International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <brief_summary>
    <textblock>
      This hospital-based, multicenter, randomized, placebo-controlled trial will assess the
      effects of misoprostol as part of active management of the third stage of labor on postpartum
      blood loss, complications, and side effects. Twelve hundred eligible women will receive
      routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo
      during or immediately after delivery. The primary outcome will be measured blood loss of
      =&gt;500 mls within one hour after enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss =&gt;500 mls within one hour after enrollment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss =&gt;1000 mls within one hour after enrollment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood loss after enrollment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level &lt;8 g/dL 24 hours after delivery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidity and mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo resembling misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>misoprostol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo resembling misoprosotl</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who have given birth to 1 or more live-born infants (para 1 or more)

          -  Vaginal delivery

        Exclusion Criteria:

          -  Refusal or inability to give informed consent

          -  Delivery regarded as abortion according to local gestational age limits

          -  Inability to take misoprostol sublingually

          -  Cesarean section

          -  Assisted vaginal delivery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindeka Mangesi</last_name>
    <role>Study Director</role>
    <affiliation>Effective Care Research Unit, East London Hospital Complex, South Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. J. Hofmeyr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Effective Care Research Unit, Frere Maternity Hospital, East London Hospital Complex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tembisa Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rob Ferreira Hospital</name>
      <address>
        <city>Nelspruit</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dora Nginza Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulago Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nigeria</country>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2005</study_first_posted>
  <last_update_submitted>May 26, 2008</last_update_submitted>
  <last_update_submitted_qc>May 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Justus Hofmyer</name_title>
    <organization>University of Witwatersrand</organization>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>Active management</keyword>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Maternal morbidity</keyword>
  <keyword>Anemia</keyword>
  <keyword>Developing countries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

